Related Experiment Videos

Association of CD36 gene polymorphisms with echo- and electrocardiographic parameters in patients with early onset

Monika Rac1, Grzegorz Kurzawski, Krzysztof Safranow

  • 1Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland.

Archives of Medical Science : AMS
|September 20, 2013
PubMed

Insights

Genetic variations in CD36 are linked to cardiac issues. Certain CD36 gene mutations may contribute to left ventricular hypertrophy and impaired diastolic function in patients with early-onset coronary artery disease.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Cardiology
  • Human Genetics

Background:

  • CD36 is crucial for long-chain fatty acid metabolism in cardiac and skeletal muscle.
  • CD36 deficiency can impair myocardial fatty acid uptake.
  • CD36 gene mutations may explain clinical variability in cardiac hypertrophy.

Purpose of the Study:

  • To examine the association between CD36 sequence variations and cardiac function.
  • To correlate CD36 gene changes with echocardiographic and electrocardiographic findings.
  • To investigate CD36 variants in Caucasian patients with early-onset coronary artery disease.

Main Methods:

  • Studied 100 Caucasian patients with early-onset coronary artery disease.
  • Performed echocardiography and electrocardiography on all participants.
  • Analyzed CD36 exons 4-6 and adjacent introns using denaturing high-performance liquid chromatography.

Main Results:

  • IVS3-6TC (rs3173798) heterozygotes showed impaired left ventricle diastolic function.
  • 573GA (rs5956) heterozygotes had a higher frequency of pseudonormal diastolic function.
  • 591AT genotype correlated with increased posterior wall thickness and lower E/A ratio, suggesting left ventricular hypertrophy.

Conclusions:

  • Specific CD36 variant alleles are associated with left ventricular hypertrophy.
  • Detected CD36 gene variations may contribute to impaired diastolic function.
  • CD36 mutations are potential contributors to cardiac dysfunction in coronary artery disease.
Abstract

Keywords:
CADCD36diastolic functionechocardiographyelectrocardiographyleft ventricular hypertrophy

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...